Evidence map›Paper›PMID 35890399›Full record

ArticlePharmaceutics2022

Multiparticulate Systems of Meloxicam for Colonic Administration in Cancer or Autoimmune Diseases.

Eva Navarro-Ruíz, Covadonga Álvarez-Álvarez, M Ángeles Peña, Carlos Torrado-Salmerón, Zaid Dahma, Paloma Marina de la Torre-Iglesias

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Royal Society open science · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Eva Navarro-RuízDepartment of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.
Covadonga Álvarez-ÁlvarezDepartment of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.ORCID 0000-0001-9327-0867
M Ángeles PeñaDepartment of Biomedical Science, Faculty of Pharmacy, University of Alcalá de Henares, Ctra Madrid-Barcelona Km 33600, 28805 Madrid, Spain.ORCID 0000-0002-0908-8286
Carlos Torrado-SalmerónDepartment of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.ORCID 0000-0002-4123-3367
Zaid DahmaDepartment of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.
Paloma Marina de la Torre-IglesiasDepartment of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.ORCID 0000-0002-7768-0978
Universidad Complutense de Madrid · ESUniversidad de Alcalá · ES

Funding

Complutense University of Madrid, Spain Research Group 910939Ministerio de Ciencia e Innovación, Spain MICINU, ref. RTI2018-093940-B-100
6 · The paper itself

Abstract

The aim of this research is the development of new colonic release systems of meloxicam (MLX) a non-steroidal anti-inflammatory drug (NSAIDs) with pH and time-dependent vehicles for cancer or autoimmune diseases. The colon has a higher pH than the rest of the gastrointestinal tract (GIT) and this can be used as a modified release strategy. Eudragit

Indexed as

autoimmune diseasecancercolonic administrationmeloxicammultiparticulate system

Identifiers

PMID35890399
PMCPMC9322124
OpenAlexW4286503245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.